Ontology highlight
ABSTRACT:
SUBMITTER: Gelsomino F
PROVIDER: S-EPMC7372524 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Gelsomino Francesco F Lamberti Giuseppe G Tiseo Marcello M Rocco Danilo D Pasello Giulia G Cecere Fabiana Letizia FL Chella Antonio A Grilli Giada G Mandruzzato Marcella M Tognetto Michele M Garassino Marina Chiara MC Macerelli Marianna M Novello Silvia S Roila Fausto F Colantonio Ida I Grossi Francesco F Fiorentino Michelangelo M Ardizzoni Andrea A
Therapeutic advances in medical oncology 20200720
<h4>Background</h4>Although immunotherapy with immune-checkpoint inhibitors (ICIs) has profoundly changed the therapeutic scenario in the treatment of advanced non-small cell lung cancer (NSCLC), trials of ICIs only enrolled NSCLC patients with common histology. Atezolizumab was approved by the United States Food and Drug Administration (US FDA) in October 2016 and by the European Medicines Agency (EMA) in September 2017 for the treatment of patients with metastatic NSCLC whose disease progresse ...[more]